BACKGROUND: Tumour-infiltrating lymphocytes (TILs) have been shown to predict survival in numerous malignancies. The importance of TILs in primary pancreatic neuroendocrine tumours (NETs) and NET liver metastases (NETLMs) has not been defined. METHODS: We identified 87 patients with NETs and 39 with NETLMs who had undergone resection. Immunohistochemistry was performed to determine TIL counts. Recurrence-free survival (RFS) and overall survival (OS) were determined using the log-rank test. RESULTS: The median follow-up time was 62 months in NET patients and 48 months in NETLM patients. Vascular invasion and histologic grade were the only independent predictors of outcome for NETs and NETLMs, respectively. Analysis of intermediate-grade NETs indicated that a dense T cell (CD3+) infiltrate was associated with a median RFS of 128 months compared with 61 months for those with low levels of intratumoral T cells (P= 0.05, univariate analysis). Examination of NETLMs revealed that a low level of infiltrating regulatory T cells (Treg, FoxP3+) was a predictor of prolonged survival (P < 0.01, univariate analysis). CONCLUSIONS: A robust T cell infiltrate is associated with improved RFS following resection of intermediate-grade NETs, whereas the presence of more Treg correlated with shorter OS after treatment of NETLMs. Further study of the immune response to intermediate-grade NETs and NETLMs is warranted.
T cell infiltrate and outcome following resection of intermediate-grade primary neuroendocrine tumours and liver metastases.
中度恶性原发性神经内分泌肿瘤和肝转移瘤切除术后T细胞浸润与预后的关系
阅读:6
作者:Katz Steven C, Donkor Charan, Glasgow Kristen, Pillarisetty Venu G, Gönen Mithat, Espat N Joseph, Klimstra David S, D'Angelica Michael I, Allen Peter J, Jarnagin William, Dematteo Ronald P, Brennan Murray F, Tang Laura H
| 期刊: | HPB (Oxford) | 影响因子: | 0.000 |
| 时间: | 2010 | 起止号: | 2010 Dec;12(10):674-83 |
| doi: | 10.1111/j.1477-2574.2010.00231.x | 研究方向: | 免疫/内分泌、神经科学、细胞生物学、肿瘤 |
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
